In November 2013, the FDA introduced a proposed rule entitled, “Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products.” Last month, the Agency announced the delay of the final regulation, saying the rule on generic drug labeling changes will come in July 2016.
In 2011, Public Citizen submitted a petition to the FDA asking the Agency to “amend 21 C.F.R. § 314.70(a) to specify that 21 C.F.R. § 314.70(b) and (c) apply to abbreviated new drug application (ANDA) holders.” In the petition Public Citizen stated that the amendment should do the following:
Public Citizen also asked the FDA to amend 21 C.F.R. § 314.150(b)(10), which allows “ANDA approval to be withdrawn if a generic drug’s approved labeling differs from that of the reference listed drug (RLD).” The organization stated that FDA should “specify that this regulation does not apply to ANDA holders permitted to supplement labeling through CBE or PAS procedures.” The final request made by Public Citizen was that “the FDA clarify that all ANDA holders are required to report safety concerns to the FDA as soon as they become aware of a clinically significant hazard.”
In response to this petition, the FDA released a proposed rule regarding generic drug labeling changes on November 13, 2013. If finalized, this rule will allow new safety information to be independently added to the labels of generic drugs, an activity which has been done to the labels of the reference products for nearly 30 years.
Currently, companies that market generic drugs cannot update the product’s label to add new safety information as it is acquired. Instead, companies must wait until the label of the branded drug is changed. As such, if the drug company learns of a safety issue that has yet to be acknowledged by the manufacturer of the branded drug, they cannot take measures to notify the public of the impending concern by making generic drug labeling changes.
If the rule is finalized, this is all going to change. Under the proposed rule, generic drug sponsors will be able to immediately modify the drug’s label to reflect any safety-related changes. This means we could potentially begin to see temporary differences between the labels of brand-name and generic drugs.
Since 2013, the FDA has received more than 23,000 comments regarding the proposed rule which would allow generic drug labeling changes. Although the content of these comments have varied, the Agency has received some feedback from companies expressing their opposition to the potential regulation. According to RAPS, the companies in disagreement, generally generic drug makers, claim that the impending regulation will “expose them to billions of dollars in new legal liabilities.” RAPS also stated that the companies’ response to the rule on generic drug labeling changes and the FDA’s delay have left many patient advocacy groups enraged.
Due to the controversial nature of the proposed rule, the FDA has been “deliberating, holding meetings, and re-opening the federal docket for more comments” over the past two years. Despite pressure from some who have been urging the rule to be finalized quickly, the Agency has taken its time. The FDA has recently said that that it is “considering several alternatives,” and wants to ensure that all financial implications as well as the benefits associated with the final rule have been taken into account.
It will be very interesting to watch how the FDA responds to this controversial topic, and we are intrigued to see what is released in seven months.
October 8, 2015
On September 28, 2015, Sen. David Vitter (R-LA) sent a letter to FDA’s Acting Commissioner, Stephen Ostroff, MD, in which he stated various concerns regarding an extensive backlog of Abbreviated New...
August 29, 2016
On Wednesday, August 24th FDA released a final guidance document, entitled “Abbreviated New Drug Application Submissions – Refuse to Receive for Lack of Justification of Impurity Limits,” which...
October 2, 2015
This week FDA finalized its draft guidance on Controlled Correspondence Related to Generic Drug Development. Although all submitted comments were considered, FDA’s revised the draft to “provide...